TY  - JOUR
AU  - Mair, Maximilian J
AU  - Hartenbach, Sabrina
AU  - Tomasich, Erwin
AU  - Maas, Sybren L N
AU  - Bosch, Sarah A
AU  - Widhalm, Georg
AU  - Eckert, Franziska
AU  - Sahm, Felix
AU  - Hainfellner, Johannes A
AU  - Hartenbach, Markus
AU  - Berghoff, Anna S
AU  - Preusser, Matthias
AU  - Albert, Nathalie L
TI  - Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma.
JO  - European journal of nuclear medicine and molecular imaging
VL  - 52
IS  - 8
SN  - 1619-7070
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - DKFZ-2025-00402
SP  - 2771-2781
PY  - 2025
N1  - 2025 Jul;52(8):2771-2781
AB  - High-grade meningiomas have high recurrence rates and limited prognosis. Radioligand therapies are approved in extracranial malignancies, but their value in brain tumours including meningiomas is unclear, as data on target expression is scarce.CNS WHO grade 2 and 3 meningioma samples were immunohistochemically stained for somatostatin receptor 2a (SSTR2a), fibroblast activation protein (FAP), and human epidermal growth factor receptors 2/3 (HER2/HER3). Target expression was correlated with (epi-)genetic tumour subtyping by DNA methylation analysis, genetic alterations, and survival.Meningioma samples of 58 patients were included. SSTR2a expression (membranous/cytoplasmic) was observed in 43/55 (78.2
KW  - Brain tumour (Other)
KW  - Fibroblast activating protein (Other)
KW  - Meningioma (Other)
KW  - Somatostatin receptor (Other)
KW  - Theranostics (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39969538
DO  - DOI:10.1007/s00259-025-07075-8
UR  - https://inrepo02.dkfz.de/record/298982
ER  -